Madrigal announces new two-year data from the compensated mash cirrhosis arm of the maestro-nafld-1 trial demonstrating potential benefit of rezdiffra™ (resmetirom) in patients with compensated mash cirrhosis

Conshohocken, pa., feb. 26, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today reported positive two-year results from the open-label compensated mash cirrhosis (f4c) arm of the phase 3 maestro-nafld-1 trial of rezdiffra (resmetirom). patients treated with rezdiffra achieved marked reductions in liver stiffness, a surrogate for fibrosis, measured by vibration-controlled transient elastography (vcte).
MDGL Ratings Summary
MDGL Quant Ranking